# Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms

> **NCT00408018** · PHASE1 · TERMINATED · sponsor: **Piramal Enterprises Limited** · enrollment: 28 (actual)

## Conditions studied

- Neoplasm

## Interventions

- **DRUG:** P276-00

## Key facts

- **NCT ID:** NCT00408018
- **Lead sponsor:** Piramal Enterprises Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-03
- **Primary completion:** 2008-08
- **Final completion:** 2008-10
- **Target enrollment:** 28 (ACTUAL)
- **Why stopped:** The decision to terminate this study after 202 mg/m2 cohort was taken as MTD achieved in other study at 185 mg/m2
- **Last updated:** 2009-01-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00408018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00408018, "Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00408018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*